JP2016503009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503009A5 JP2016503009A5 JP2015547522A JP2015547522A JP2016503009A5 JP 2016503009 A5 JP2016503009 A5 JP 2016503009A5 JP 2015547522 A JP2015547522 A JP 2015547522A JP 2015547522 A JP2015547522 A JP 2015547522A JP 2016503009 A5 JP2016503009 A5 JP 2016503009A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- alkoxy
- heterocycloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 31
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- -1 heterocycloalkyloxy- Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- WUVSMDJSLFKKRF-UHFFFAOYSA-N 5-bromo-n-[(2,6-dimethyl-4-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methylbenzamide Chemical compound C=1C(Br)=CC(C(=O)NCC=2C(C=C(C)NC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 WUVSMDJSLFKKRF-UHFFFAOYSA-N 0.000 claims 1
- CSBJKJZYCQDIJS-UHFFFAOYSA-N 5-chloro-n-[(2,6-dimethyl-4-oxo-1h-pyridin-3-yl)methyl]-2-methyl-3-(1-methylpiperidin-4-yl)oxybenzamide Chemical compound C1CN(C)CCC1OC1=CC(Cl)=CC(C(=O)NCC=2C(C=C(C)NC=2C)=O)=C1C CSBJKJZYCQDIJS-UHFFFAOYSA-N 0.000 claims 1
- YWSJZMCKTAFJMJ-UHFFFAOYSA-N 5-chloro-n-[(2,6-dimethyl-4-oxo-1h-pyridin-3-yl)methyl]-2-methyl-3-piperidin-4-yloxybenzamide Chemical compound N1C(C)=CC(=O)C(CNC(=O)C=2C(=C(OC3CCNCC3)C=C(Cl)C=2)C)=C1C YWSJZMCKTAFJMJ-UHFFFAOYSA-N 0.000 claims 1
- QRJQILUUCRRLJD-UHFFFAOYSA-N 5-chloro-n-[(2,6-dimethyl-4-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methylbenzamide Chemical compound C=1C(Cl)=CC(C(=O)NCC=2C(C=C(C)NC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 QRJQILUUCRRLJD-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005969 Bone giant cell tumour Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZTXZUCUECHTAGN-HCGLCNNCSA-N C(C1=CC=CC=C1)NC(=O)[C@@H]1CC[C@H](CC1)OC=1C(=C(C(=O)NCC2=C(NC(=CC2=O)C)C)C=C(C1)Cl)C Chemical compound C(C1=CC=CC=C1)NC(=O)[C@@H]1CC[C@H](CC1)OC=1C(=C(C(=O)NCC2=C(NC(=CC2=O)C)C)C=C(C1)Cl)C ZTXZUCUECHTAGN-HCGLCNNCSA-N 0.000 claims 1
- GJFHXNSEWLSRRJ-MEMLXQNLSA-N CCN([C@H]1CC[C@@H](CC1)N(C)C)c1cc(Cl)cc(C(=O)NCc2c(C)[nH]c(C)cc2=O)c1C Chemical compound CCN([C@H]1CC[C@@H](CC1)N(C)C)c1cc(Cl)cc(C(=O)NCc2c(C)[nH]c(C)cc2=O)c1C GJFHXNSEWLSRRJ-MEMLXQNLSA-N 0.000 claims 1
- JICRWEWBJPMGQL-WGSAOQKQSA-N ClC=1C=C(C(=C(C(=O)NCC2=C(NC(=CC2=O)C)C)C1)C)O[C@@H]1CC[C@H](CC1)N(C)C Chemical compound ClC=1C=C(C(=C(C(=O)NCC2=C(NC(=CC2=O)C)C)C1)C)O[C@@H]1CC[C@H](CC1)N(C)C JICRWEWBJPMGQL-WGSAOQKQSA-N 0.000 claims 1
- HCKGBGGSWQXTRY-MEMLXQNLSA-N ClC=1C=C(C(=C(C(=O)NCC2=C(OC(=CC2=O)C)C)C1)C)N(CC)[C@@H]1CC[C@H](CC1)N(C)C Chemical compound ClC=1C=C(C(=C(C(=O)NCC2=C(OC(=CC2=O)C)C)C1)C)N(CC)[C@@H]1CC[C@H](CC1)N(C)C HCKGBGGSWQXTRY-MEMLXQNLSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 201000002847 Cowden syndrome Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000011143 bone giant cell tumor Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- ZIDDCTZSFNCYRD-UHFFFAOYSA-N n-[(2,6-dimethyl-4-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(C=C(C)NC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 ZIDDCTZSFNCYRD-UHFFFAOYSA-N 0.000 claims 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736645P | 2012-12-13 | 2012-12-13 | |
| US61/736,645 | 2012-12-13 | ||
| US201361777443P | 2013-03-12 | 2013-03-12 | |
| US61/777,443 | 2013-03-12 | ||
| PCT/US2013/074558 WO2014107277A1 (en) | 2012-12-13 | 2013-12-12 | Enhancer of zeste homolog 2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503009A JP2016503009A (ja) | 2016-02-01 |
| JP2016503009A5 true JP2016503009A5 (enExample) | 2017-01-05 |
Family
ID=51062419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547522A Pending JP2016503009A (ja) | 2012-12-13 | 2013-12-12 | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9382234B2 (enExample) |
| EP (1) | EP2931707A4 (enExample) |
| JP (1) | JP2016503009A (enExample) |
| KR (1) | KR20150095779A (enExample) |
| CN (1) | CN104968646B (enExample) |
| AU (1) | AU2013371541B2 (enExample) |
| BR (1) | BR112015014090A2 (enExample) |
| CA (1) | CA2894657A1 (enExample) |
| RU (1) | RU2015127822A (enExample) |
| WO (1) | WO2014107277A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894216A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| EP2935264B1 (en) | 2012-12-21 | 2017-10-18 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| CN105473580A (zh) | 2013-07-10 | 2016-04-06 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste同源物增强子2抑制剂 |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2016101956A2 (en) | 2014-12-23 | 2016-06-30 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| CA3018270A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| WO2018086592A1 (zh) | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2019152419A1 (en) | 2018-01-31 | 2019-08-08 | Mirati Therapeutics, Inc | Prc2 inhibitors |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| CN109801676B (zh) * | 2019-02-26 | 2021-01-01 | 北京深度制耀科技有限公司 | 一种用于评价化合物对基因通路活化作用的方法及装置 |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| CA3142711A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| BR112022001154A2 (pt) * | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Terapias de inibição de ezh2 para o tratamento de cânceres |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| WO2003088903A2 (en) | 2002-04-17 | 2003-10-30 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| TW200410921A (en) * | 2002-11-25 | 2004-07-01 | Hoffmann La Roche | Mandelic acid derivatives |
| CN101023057A (zh) * | 2004-05-06 | 2007-08-22 | 赛特凯恩蒂克公司 | 某些化学品、组合物及方法 |
| US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| SG10201608579UA (en) | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| JP6461802B2 (ja) | 2012-10-15 | 2019-01-30 | エピザイム，インコーポレイティド | 置換ベンゼン化合物 |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
-
2013
- 2013-12-12 BR BR112015014090A patent/BR112015014090A2/pt not_active IP Right Cessation
- 2013-12-12 CA CA2894657A patent/CA2894657A1/en not_active Abandoned
- 2013-12-12 CN CN201380072411.5A patent/CN104968646B/zh not_active Expired - Fee Related
- 2013-12-12 JP JP2015547522A patent/JP2016503009A/ja active Pending
- 2013-12-12 US US14/651,711 patent/US9382234B2/en not_active Expired - Fee Related
- 2013-12-12 EP EP13870106.5A patent/EP2931707A4/en not_active Withdrawn
- 2013-12-12 KR KR1020157018234A patent/KR20150095779A/ko not_active Withdrawn
- 2013-12-12 WO PCT/US2013/074558 patent/WO2014107277A1/en not_active Ceased
- 2013-12-12 AU AU2013371541A patent/AU2013371541B2/en not_active Ceased
- 2013-12-12 RU RU2015127822A patent/RU2015127822A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503009A5 (enExample) | ||
| RU2015127822A (ru) | Ингибиторы энхансера гомолога 2 белка zeste | |
| JP2016517878A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| CN101142198B (zh) | 用于治疗疾病的异*唑坎布雷它斯丁衍生物 | |
| JP2019505541A5 (enExample) | ||
| JP2017530999A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2014526549A5 (enExample) | ||
| RU2017116598A (ru) | Соединения и композиции для модуляции киназной активности мутантов egfr | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2016516043A5 (enExample) | ||
| JP2010526129A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2021133444A (ru) | Производные бензимидазола в качестве модуляторов ror-гамма | |
| JP2015524472A5 (enExample) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2010538076A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2017532360A5 (enExample) | ||
| JP2014520809A5 (enExample) | ||
| JP2016540811A5 (enExample) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 |